Sector News

Novartis buys 12.8 percent stake in BioLineRX in co-development deal

December 17, 2014
Life sciences
(Reuters) – Swiss drugmaker Novartis AG bought a 12.8 percent stake in Israeli biopharmaceutical company BioLineRX Ltd as part of a multi-year collaboration deal, BioLineRX said on Tuesday.
 
Under the agreement, Novartis, which invested an initial $10 million, will evaluate projects presented by BioLineRX for development and future licensing, the Israeli firm said in a statement. They hope to develop up to three clinical projects.
 
Novartis acquired an initial 5 million American depositary shares of BioLineRx in a private transaction at $2.00 a share.
 
The partnership will be transformative for BioLineRX, said Chief Executive Kinneret Savitsky, and will give Novartis, one of the world’s largest pharmaceutical companies, access to Israeli research institutions, hospitals and biotech start-ups.
 
Once a project is selected, Novartis will pay BioLineRx an option fee of $5 million and fund half the remaining development costs in the form of an additional equity investment in BioLineRx.
 
The companies agreed to limit how big a share Novartis can buy of BioLineRX, but the amount was not disclosed, a BioLineRX spokeswoman said.
 
Novartis will have an exclusive right of first negotiation to license from BioLineRx each project.
 
(Reporting by Ari Rabinovitch; Editing by Tova Cohen and David Holmes)

Related News

April 10, 2021

Genentech aims high with new diversity goals, including doubling hires and spending $1B with diverse suppliers

Life sciences

Quita Highsmith, Genentech’s chief diversity officer, is helping the pharma double down on diversity and inclusion goals with a new 2025 plan. 

April 10, 2021

Merck CEO Frazier joins army of Black execs speaking out on restrictive voting-rights laws

Life sciences

Merck CEO Kenneth Frazier teamed up with former American Express executive Kenneth Chenault to protest a voting-rights law passed recently in Georgia.

April 10, 2021

Zimmer Biomet bundles robotic surgery, apps and digital health programs into one orthopedics package

Life sciences

By bringing together big data and robotic procedures, the ultimate goal of the connected suite is to take some of the guesswork out of orthopedic medicine. 

Send this to a friend